Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy

Giuseppe Gritti; Andrea Gianatti; Fiorella Petronzelli; Rita De Santis; Chiara Pavoni; Riccardo Lorenzo Rossi; Laura Cattaneo; Luigi Giusto Spagnoli; Silvia Ferrari; Andrea Rossi; Anna Maria Barbui; Alessandro Rambaldi

doi:10.18632/oncotarget.25064

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy

PDF | How to cite

Oncotarget. 2018; 9:17256-17256. https://doi.org/10.18632/oncotarget.25064

Metrics: PDF 1744 views | ?

Giuseppe Gritti¹, Andrea Gianatti², Fiorella Petronzelli³, Rita De Santis³, Chiara Pavoni¹, Riccardo Lorenzo Rossi⁴, Laura Cattaneo², Luigi Giusto Spagnoli⁵, Silvia Ferrari¹, Andrea Rossi¹, Anna Maria Barbui¹ and Alessandro Rambaldi^1,6

¹Hematology and Bone Marrow Transplant Units, Ospedale Papa Giovanni XXIII, Bergamo, Italy
²Pathology Unit, Ospedale Papa Giovanni XXII, Bergamo, Italy
³Sigma Tau S.p.A. Biotech Products R and D, Pomezia, Italy
⁴Bioinformatics, Istituto Nazionale Genetica Molecolare, Milan, Italy
⁵Department of Biomedicine and Prevention, Università di Roma Tor Vergata, Rome, Italy
⁶Department of Oncology and Oncohematology, Università degli Studi di Milano, Milan, Italy

Published: March 30, 2018

This article has been corrected: The online version of figure 3 has been corrected:

Original article: Oncotarget. 2018; 9:9766-9775 DOI: https://doi.org/10.18632/oncotarget.23919.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25064

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy